Dribendazole

This classification denotes an antihelminthic agent with the molecular formula C15H19N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5491IVP21O, chemically known as carbamic acid, (5-(cyclohexylthio)-1h-benzimidazol-2-yl)-,methyl ester but generally known as dribendazole, which bears US NIH Compound Identifier 170311. European Medicines Agency schedules Dribendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06399MIG. The term DRIBENDAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). DRIBENDAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dribendazole under HS 29339990 and SITC 51577. As of Q4 2014, DRIBENDAZOLE remains the US FDA Preferred Term for this commodity. Dribendazole bears US NLM identifiers UMLS ID C1880410 and NCI Concept Code C65481. SMILES: S(C1CCCCC1)C1CC2[NH]C(NC2CC1)NC(=O)OC.